By far, the largest acquisition of 2024 was Novo Holdings' yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion.

The discontinuation caps off a turbulent development path for izokibep, which in September 2023 produced disappointing ...

Around 25 companies have gone public this year, most of them in the early months. Most have tumbled from their original offer ...

The EPIC Act has been proposed with bipartisan and industry support to give small molecule drugs the same protection against ...

BNT327, now in early-phase trials, is part of a class of drugs that could one day challenge Keytruda’s dominance. BioNTech ...

With nearly 90% of patients showing no detectable cancer cells after treatment, J&J and Legend’s Carvykti could stave off ...

The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...

Ending the diagnostic journey for patients, particularly those with rare diseases, improves patients' quality of life while ...

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...

In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified ...

Carisma’s second workforce reduction this year likely leaves the company with 44 full-time employees as turns its focus to ...

Relmada Therapeutics will halt two Phase III trials of a major depressive disorder drug after a futility assessment and ...